Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 0.38 |
| ▸ | PPARD | Q03181 | 15/20 | 0.38 |
| ▸ | PPARG | P37231 | 6/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3957557 | 0.88 | PPARD (0.48) | PPARAPPARDPPARG | |
| SCHEMBL3964640 | 0.86 | TRPV1 (0.44) | PPARAPPARDPPARG | |
| SCHEMBL3962072 | 0.85 | PPARA (0.40) | PPARAPPARDPPARGCYP2C9CYP2C19 | |
| SCHEMBL3964305 | 0.77 | PPARD (0.55) | PPARAPPARD | |
| SCHEMBL3964286 | 0.77 | SLC22A12 (0.35) | PPARAPPARDPPARG | |
| SCHEMBL3964614 | 0.77 | PPARD (0.46) | PPARAPPARDPPARG | |
| SCHEMBL3963247 | 0.76 | PPARD (0.39) | PPARAPPARDPPARG | |
| SCHEMBL4794898 | 0.75 | PPARA (0.39) | PPARAPPARDPPARGCYP2C9CYP2C19 | |
| SCHEMBL13791835 | 0.75 | PPARA (0.42) | PPARAPPARDPPARG | |
| SCHEMBL3964385 | 0.74 | PPARD (0.46) | PPARAPPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | claimed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | claimed |
| EP-1706386-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-04 | — | — | EP | claimed |
| WO-2005066136-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | claimed |
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | PPARD, PPARA, PPARG | PPARA 2/4885PPARD 1/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.